|

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

RECRUITINGSponsored by Takeda
Actively Recruiting
SponsorTakeda
Started2019-09-05
Est. completion2026-08-26
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04592523

Summary

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

1. With ALK-positive advanced or metastatic NSCLC.
2. Who initiate brigatinib for the first time.

Exclusion Criteria:

1. Treated with brigatinib outside of the locally approved label in Korea.
2. Whom brigatinib is contraindicated as per product label.
3. Participating in other clinical trials of NSCLC treatment.

Conditions4

Anaplastic Lymphoma KinaseCancerCarcinoma, Non-Small-Cell LungLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.